Indian Pharmaceutical Market Forecast 2016-2026

07 Dec, 2015, 09:00 ET from Visiongain

LONDON, December 7, 2015 /PRNewswire/ --

- Future Prospects for Leading Companies in Generics, OTC, Originator Products and Biosimilars Propelled by Growth in Key Therapeutic Areas

What can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 194-page report provides 117 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of the Indian pharmaceutical market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects 

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications 

How will submarkets perform to 2026? Our study forecasts revenues in the following Indian Pharmaceutical submarkets:
• Generic Drugs
• Over-The-Counter (OTC) Drugs
• Patented Drugs
• Biosimilars

See revenue forecasts for the leading therapeutic areas
How will leading therapeutic areas perform to 2026? Our study forecasts revenues in therapeutic areas including:
• Infectious disease drugs
• Cardiovascular disease drugs
• Gastro-intestinal drugs
• Respiratory disease
• Pain relief / analgesics
• Diabetes
• Vitamins / Minerals / Nutrients

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


• Dermatology
• Central Nervous System (CNS)
• Gynaecology

Leading companies and potential for market growth 

Overall revenue for the Indian Pharmaceutical market will reach $36.18bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. An ageing population, increasing access to healthcare and increasing incidence of chronic diseases, especially diabetes and cardiovascular disease, will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:
• Sun Pharmaceutical Industries Limited
• Abbott Healthcare Private Limited (Abbott India)
• Cipla Ltd.
• Cadila Healthcare Ltd.
• GlaxoSmithKline Pharmaceuticals Limited (GSK India)
• Pfizer Limited. India
• Lupin Pharmaceuticals, Inc.,

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 10 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Indian pharmaceutical industry? 

Our new report discusses issues and events affecting the Indian pharmaceutical market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging drug types with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Indian Pharmaceutical Market Forecast 2015-2026 report helps you
In summary, our 194-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Indian Pharmaceutical market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading pharmaceutical products in the following areas: Infectious disease drugs, Cardiovascular disease drugs, Gastro-intestinal drugs, Respiratory disease , Pain relief / analgesics, Diabetes, Vitamins / Minerals / Nutrients, Dermatology, Central Nervous System (CNS), Gynaecology
• Revenue forecasts to 2026 for the leading drug types - generics, OTC products, patented drugs and biosimilars
• Assessment of leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Indian Pharmaceutical market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1539/Indian-Pharmaceutical-Market-Forecast-2016-2026

Companies Listed
Sun Pharmaceuticals Industries Ltd
Abbott India
Cipla
Cadila Healthcare Ltd.
Mankind
Alkem
GSK India
Macleods
Pfizer India
Lupin
Intas Pharma
Torrent Pharma
Emcure
Sanofi India
Aristo Pharma
Dr Reddy's Labs
Glenmark Pharma
USV
Micro Labs
Alembic
Novartis India
Ipca Labs
Wockhardt
FDC
Unichem
MSD Pharma
Cadila Pharma
Merck KGaA
Franco India
Indoco
Eris Lifesciences
The Himalaya Drug Company
Divis Laboratories
Blue Cross Laboratories Ltd.
JB Chemicals
Bharat Serums
AstraZeneca
Meyer Organics
Raptakos, Brett & Co. Ltd
Akumentis Healthcare Ltd
Hetero Drugs Ltd
Wallace + Indi Pharma
Medley Pharmaceuticals Ltd
Janssen
Win-Medicare
Fourrts (India) Laboratories Pvt, Ltd
Ajanta Pharma Ltd
Biocon Ltd
Apex Laboratories Pvt. Ltd
Albert David Ltd
Claris Lifesciences
Lonza
Bayer
Natco
Shantha Biotechnics
Merieux Alliance
Gennova Biopharmaceuticals
Virchow Biotech
Bioviz Technologies
Gland Pharma
Serum Institute of India
Zenotech Laboratories
Epirus Biopharmaceuticals
Sandoz (Novartis)
Novartis
Caraco Pharmaceutical Laboratories
Able Labs
Cattern Chemical Inc.
DUSA Pharmaceuticals Inc.
Intrexon
URL
Merck
Pharmalucence
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Ltd.
Daiichi Sankyo
Piramal Healthcare
Sanofi
Cadila Pharmaceuticals Ltd.
Medpro Pharmaceutica (Pty) Ltd.
Megafine Pharma
Novo Nordisk

 

Organisations Mentioned in the Report
Central Drugs Standard Control Organisation (CDSCO)
Competition Commission of India (CCI)
Drug Technical Advisory Board (DTAB)
Drug Consultative Committee (DCC)
European Medicines Agency
High Court of Punjab and Haryana
Indian Patent Office
(Japan's) Minstry of Health, Labour and Welfare (MHLW)
Medical Council of India
(Indian) Ministry of Health
National AIDS Control Organisation (NACO)
(Australia's) Therapeutic Goods Administration (TGA)
UK Medicines & Healthcare Products Regulatory Agency (MHRA)
US Federal Trade Commission (FTC)
US Food and Drug Administration (FDA)
UNAIDS
World Bank
World Health Organisation (WHO)
World Trade Organisation (WTO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


SOURCE Visiongain